We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock

Delisted

SYRS was delisted on the 19th of March, 2025.

Name Holding Trade Value Shares
Change
Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$5.67M
AG
2
Artal Group
Luxembourg
$3.94M +$46.2K +11,915 +0.8%
FP
3
Flagship Pioneering
Massachusetts
$2.65M
APM
4
Avidity Partners Management
Texas
$2.42M +$17.9K +4,630 +0.5%
SB
5
Samsara BioCapital
California
$2.35M
CA
6
CHI Advisors
New York
$2.05M +$2.98M +767,445 New
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$1.93M
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.3M +$56.2K +14,492 +3%
DCM
9
DAFNA Capital Management
California
$710K
OFM
10
Omega Fund Management
Massachusetts
$671K
ABG
11
Ally Bridge Group
New York
$665K -$2.4M -619,277 -71%
BlackRock
12
BlackRock
New York
$502K -$75.8K -19,565 -9%
ECM
13
ExodusPoint Capital Management
New York
$325K +$339K +87,390 +256%
Goldman Sachs
14
Goldman Sachs
New York
$281K +$360K +92,824 +748%
LPL Financial
15
LPL Financial
California
$222K +$164K +42,209 +103%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$222K +$48.7K +12,563 +18%
Millennium Management
17
Millennium Management
New York
$209K -$50.9K -13,137 -14%
LCP
18
LGT Capital Partners
Switzerland
$147K
BCM
19
Bridgeway Capital Management
Texas
$132K +$192K +49,500 New
Renaissance Technologies
20
Renaissance Technologies
New York
$122K -$5.43K -1,400 -3%
State Street
21
State Street
Massachusetts
$88.5K
Marshall Wace
22
Marshall Wace
United Kingdom
$81.6K +$118K +30,551 New
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$80.7K +$117K +30,226 New
Corient Private Wealth
24
Corient Private Wealth
Florida
$71.2K +$103K +26,666 New
T. Rowe Price Associates
25
T. Rowe Price Associates
Maryland
$61K +$40.3K +10,400 +86%